Leica Biosystems
A Danaher company supplying pathology instruments, reagents, software, and diagnostic solutions for tissue-based cancer diagnosis.
Last updated August 31, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Leica Biosystems is a medical-device, clinical-diagnostics, and pathology-technology company operating as a division of Danaher Corporation. Its business is focused on the laboratory workflow used to examine tissue and cells, particularly in cancer diagnosis. The company supplies instruments, consumables, reagents, software, and related services for histology, immunohistochemistry, cytology, molecular pathology, and digital pathology. The company traces its origins to Precision Engineering, established in 1872. Over time, the business developed into a supplier of laboratory and microscopy technologies and became associated with the Leica brand. Leica Biosystems is distinct from other Leica-branded businesses, including Leica Camera and Leica Geosystems; its activities are concentrated on biomedical research and clinical pathology rather than photography or surveying. Its portfolio covers multiple stages of the pathology process. Histology products support the preparation of tissue specimens, including sectioning and related laboratory procedures. Staining systems and reagents help laboratories apply routine and specialized stains to tissue sections. Immunohistochemistry and molecular pathology products are used to identify proteins, biomarkers, and other characteristics that can assist disease classification and treatment selection. Digital pathology products, including the Aperio platform, support slide scanning, image management, analysis, and remote review. Leica Biosystems presents itself as an integrated pathology-solutions provider rather than solely as an instrument manufacturer. Its offerings are designed to connect specimen preparation, staining, scanning, interpretation, and laboratory workflow management. This positioning is particularly relevant to oncology, where diagnostic decisions may depend on the coordinated use of morphology, immunostaining, molecular information, and digital image analysis. The company also participates in companion-diagnostics and advanced-assay development, linking pathology testing with targeted cancer therapies and clinical research. The company has an international operating footprint, with activities identified in Germany, the United Kingdom, the Netherlands, Australia, India, China, Singapore, Mexico, and the United States. It has maintained research and development activity in Danvers, Massachusetts, including work related to companion diagnostics for cancer drugs. In 2024, it announced plans to relocate its Companion Diagnostics and Advanced Assays business to Newcastle, United Kingdom, indicating a continuing concentration of specialized assay capabilities in the company’s European operations. Leica Biosystems has expanded its capabilities through acquisitions and partnerships. The acquisition of Aperio in 2012 strengthened its position in digital pathology and ePathology. Its 2014 agreement to purchase Devicor Medical Products broadened its exposure to breast-biopsy devices. In 2022, it announced the acquisition of Cell IDx, a company associated with multiplex staining panels and tissue imaging and analysis services. The company has also collaborated with Galena Biopharma on companion-diagnostic work related to a breast-cancer vaccine and partnered with Mayo Clinic’s Department of Laboratory Medicine and Pathology on cytogenetics imaging software. As a Danaher subsidiary, Leica Biosystems operates within a larger life-sciences and medical-technology group. It serves hospitals, commercial laboratories, academic and research institutions, pharmaceutical companies, and other pathology users. Its current strategic identity is centered on improving the consistency, efficiency, and information content of tissue-based diagnosis through connected instruments, assays, automation, and digital interpretation tools.
History
Leica Biosystems traces its origins to Precision Engineering, founded in 1872. The company’s historical development formed part of the broader evolution of Leica-branded precision and optical technologies, although Leica Biosystems is a separate medical-technology business from Leica Camera and Leica Geosystems. Its modern activities are concentrated on pathology laboratories, clinical diagnostics, biomedical research, and medical devices. The company developed a broad pathology portfolio covering the preparation and examination of tissue specimens. Histology instruments support the production of tissue sections for microscopic review, while staining platforms and reagents apply routine, special, and immunohistochemical stains. These technologies are used by hospital and commercial laboratories in the diagnosis and classification of disease, especially cancer. The business also expanded into molecular pathology, companion diagnostics, and digital pathology, areas in which tissue morphology and biomarker information can be combined to support treatment decisions. A significant step in its digital-pathology development came in October 2012, when Leica Biosystems acquired Aperio, an ePathology company. Aperio brought digital slide scanning and image-management expertise, strengthening Leica Biosystems’ ability to provide technologies beyond conventional microscopes and laboratory instruments. Digital pathology became an important component of the company’s integrated workflow model, connecting slide preparation with scanning, image review, analysis, and data management. In October 2014, Leica Biosystems announced that it would purchase Devicor Medical Products, headquartered in Cincinnati. Devicor produced medical devices used in breast biopsies. The transaction broadened Leica Biosystems’ medical-device activities beyond laboratory pathology and added a connection to breast-cancer diagnosis and tissue acquisition. Leica Biosystems also established research and development activity related to companion diagnostics. A facility in Danvers, Massachusetts, operating since August 2012, concentrated on companion diagnostics for cancer drugs. The company partnered with Galena Biopharma on the development of companion diagnostics connected with a breast-cancer vaccine. It also partnered with the Mayo Clinic’s Department of Laboratory Medicine and Pathology in the development of cytogenetics imaging software, reflecting the company’s interest in applying imaging and software to specialized diagnostic interpretation. In November 2022, Leica Biosystems announced the acquisition of Cell IDx, based in San Diego, California. Cell IDx was associated with multiplex staining panels, tissue staining, and imaging and analysis services. The acquisition added capabilities relevant to multiplexed tissue analysis and image interpretation, complementing Leica Biosystems’ existing work in staining, digital pathology, and advanced assays. In 2024, the company announced the relocation of its Companion Diagnostics and Advanced Assays business to Newcastle in the United Kingdom. The move represented an organizational and geographic change in a specialized part of the business and underscored the continuing importance of companion diagnostics and advanced assay development to Leica Biosystems’ strategy. Leica Biosystems is headquartered in Wetzlar, Germany, and operates internationally, with identified operations in the United Kingdom, the Netherlands, Australia, India, China, Singapore, Mexico, and the United States. Its business serves pathology laboratories, hospitals, researchers, pharmaceutical partners, and other users of tissue-based diagnostic technologies. As a Danaher division, it is part of a larger life-sciences and medical-technology group. Its present model combines instruments, consumables, assays, software, imaging, and service capabilities in an effort to make pathology workflows more standardized, automated, and digitally connected.
- 2024
Relocation of advanced-assays activities to Newcastle
[1]Leica Biosystems announced the relocation of its Companion Diagnostics and Advanced Assays business to Newcastle, United Kingdom.
- 2022
Acquisition of Cell IDx
[1]Leica Biosystems announced the acquisition of Cell IDx and its capabilities in multiplex staining, tissue imaging, and analysis services.
- 2014
Agreement to purchase Devicor Medical Products
[1]The company announced plans to purchase Devicor Medical Products, a manufacturer of devices used in breast biopsies.
- 2012
Danvers companion-diagnostics facility begins operation
[1]A research and development facility in Danvers, Massachusetts, began operating with a focus on companion diagnostics for cancer drugs.
- 2012
Acquisition of Aperio
[1]Leica Biosystems acquired Aperio, expanding its capabilities in ePathology, digital slide scanning, and image-based pathology workflows.
- 1872
Origins as Precision Engineering
[1]The company traces its origins to Precision Engineering, established in 1872.
Products and positioning
An integrated, precision-oriented pathology platform combining specimen preparation, staining, diagnostics, digital imaging, and workflow technologies for clinical laboratories and cancer care.
Automated immunohistochemistry and in situ hybridization system
BOND-III
BOND-III is an automated pathology platform associated with immunohistochemistry and in situ hybridization workflows. It is designed to automate the application of diagnostic stains and related laboratory steps, helping pathology laboratories process tissue specimens with greater procedural consistency and throughput.
Digital pathology · 2012
Aperio Digital Pathology
Aperio is Leica Biosystems’ digital-pathology platform family, originating from the company’s acquisition of Aperio in 2012. It encompasses technologies for scanning glass slides, managing digital images, and supporting image review and analysis. The platform extends pathology workflows from physical microscopy into networked and software-supported environments.
Histology instruments
HistoCore
HistoCore is a Leica Biosystems range of histology instruments and laboratory workflow technologies. The family supports stages of tissue preparation and sectioning used before microscopic or digital examination. It represents the company’s focus on integrating instruments and consumables across routine pathology laboratory processes.
Clinical diagnostics
Companion diagnostics and advanced assays
Leica Biosystems develops companion-diagnostic and advanced-assay capabilities intended to connect pathology testing with cancer-drug development and treatment selection. These activities include biomarker-oriented testing and specialized tissue-analysis methods. The company operated a related research and development facility in Danvers and announced a later relocation of the business to Newcastle.
Marketing campaigns
- Galena Biopharma companion-diagnostics collaboration
United States
Leica Biosystems partnered with Galena Biopharma to develop companion diagnostics associated with a breast-cancer vaccine. The collaboration connected pathology testing and biomarker development with an oncology therapeutic program.
- Mayo Clinic cytogenetics imaging-software partnership
United States
Leica Biosystems partnered with the Mayo Clinic’s Department of Laboratory Medicine and Pathology to develop software for cytogenetics imaging, extending the company’s interest in image-assisted diagnostic workflows.
Brand decisions
2024
Relocate Companion Diagnostics and Advanced Assays businessStrategyBackground
Leica Biosystems’ companion-diagnostics and advanced-assay activities had been associated with its research and development presence in Danvers, Massachusetts.
Action taken
The company announced the relocation of the business to Newcastle, United Kingdom.
2022
Acquire Cell IDxM&ABackground
Cell IDx supplied or supported multiplex staining panels, tissue staining, and imaging and analysis services relevant to advanced pathology workflows.
Action taken
Leica Biosystems announced the acquisition of Cell IDx in November 2022.
Aftermath
The acquisition added capabilities in multiplexed tissue staining and image analysis to Leica Biosystems’ pathology portfolio.
2014
Purchase Devicor Medical ProductsM&ABackground
Devicor Medical Products manufactured devices used in breast biopsies, offering Leica Biosystems an expansion into tissue-acquisition devices related to breast-cancer diagnosis.
Action taken
Leica Biosystems announced in October 2014 that it would purchase Devicor Medical Products.
2012
Acquire AperioM&ABackground
Aperio provided ePathology capabilities at a time when digital slide scanning and image-based pathology were becoming important extensions of conventional laboratory microscopy.
Action taken
Leica Biosystems acquired Aperio in October 2012.
Aftermath
The transaction strengthened Leica Biosystems’ digital pathology and ePathology portfolio.
Recent events
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/leica-biosystems · Editorial policy · How profiles are compiled